Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-2.61Last Year’s EPS
-0.75Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a broadly positive view: Zealand Pharma finished 2025 with a strong cash position, a large Roche upfront and a profitable year, multiple high-impact near-term clinical catalysts (petrelintide Phase II readout, survodutide Phase III readouts) and a positive Phase I for ZP9830. Management outlined ambitious Phase III plans and significant R&D expansion supported by partnerships. Offsetting this optimism are meaningful operating expense increases in 2026, revenue dependence on milestone timing and partner execution, and market-level uncertainties around tolerability, persistence and pricing in the obesity space. On balance, the highlights—strong finances, validated partnerships, multiple upcoming data readouts and positive early clinical signals—outweigh the lowlights.Company Guidance
Strong 2025 Financials and Cash Position
Revenue of DKK 9.2 billion for FY2025 driven by upfront payment from Roche; net positive result of DKK 6.5 billion; year-end cash position of DKK 15.1 billion strengthened by the DKK 9.2 billion upfront.
Robust R&D Investment and Controlled 2025 OpEx
Net operating expenses (excl. other items) totaled DKK 2.1 billion in 2025, within the guided range of DKK 2.0–2.3 billion; 76% of 2025 OpEx was dedicated to R&D, reflecting focus on clinical advancement.
Major Partnerships Fueling Pipeline Value
Landmark collaboration with Roche for petrelintide (balanced profit share in U.S./Europe and shared development/commercial rights) and partnership with Boehringer Ingelheim for survodutide position the company to leverage external capabilities and retain significant franchise value.
Near-Term Catalysts: Petrelintide Phase II Readout and Phase III Plans
Top-line data from the Phase II ZUPREME-1 petrelintide trial (n=494; mean baseline BMI ~37) expected this quarter; company expects to use results to finalize and initiate Phase IIIa later this year. Target product profile aims for ~15%–20% body weight reduction in Phase III with improved tolerability vs incretin therapies.
Survodutide Program with Multiple Key Readouts in 2026
Boehringer’s 76-week SYNCHRONIZE-1 obesity trial results expected H1 2026; prior 46-week Phase II showed weight loss up to 19%. Broader Phase III obesity and large MASH Phase III programs (including moderate–advanced fibrosis and cirrhosis cohorts) are ongoing, with CV outcome data planned.
Positive First-in-Human Kv1.3 (ZP9830) Phase I Readout
ZP9830 single-administration Phase I showed it was very well tolerated with no serious/severe adverse events or dose-limiting findings; PK increased dose-proportionally and PD indicated target engagement. MAD results and Phase Ib/IIa progression planned in H2 2026.
Significant Potential Milestone Upside
Company noted eligibility for potential milestone payments of up to USD 700 million in 2026 (including a USD 125 million anniversary payment and a USD 575 million development milestone contingent on Phase IIIa initiation); management also referenced further USD 575 million receipts tied to Phase III program milestones.
Organizational Strength and Sustainability Progress
Headcount increased 41% in 2025 while maintaining a high employee engagement score of 8.9/10 and low turnover of 7.8%. Committed to science-based targets and joined the UN Global Compact.
ZLDPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZLDPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $61.73 | $60.42 | -2.13% |
Nov 13, 2025 | $78.72 | $80.50 | +2.26% |
Aug 14, 2025 | $53.67 | $55.02 | +2.50% |
May 08, 2025 | $68.22 | $63.26 | -7.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zealand Pharma (ZLDPF) report earnings?
Zealand Pharma (ZLDPF) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Zealand Pharma (ZLDPF) earnings time?
Zealand Pharma (ZLDPF) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLDPF EPS forecast?
ZLDPF EPS forecast for the fiscal quarter 2026 (Q1) is -2.61.